Shield Therapeutics’ interim results highlight a momentous year to date, with the FDA approval of primary asset Feraccru/Accrufer, for the treatment of iron deficiency (ID) in adults with any underlying cause. Royalties received from early sales of the product in the UK and Germany by partner Norgine are encouraging. The AEGIS-H2H study reported positive data, strengthening the product’s profile and leading to a €2.5m development milestone from Norgine. We expect a further ra
08 Aug 2019
Shield Therapeutics - The land of opportunity awaits Accrufer
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Shield Therapeutics - The land of opportunity awaits Accrufer
Shield Therapeutics Plc (STX:LON) | 1.4 0 (-1.8%) | Mkt Cap: 10.8m
- Published:
08 Aug 2019 -
Author:
Dr Susie Jana -
Pages:
3
Shield Therapeutics’ interim results highlight a momentous year to date, with the FDA approval of primary asset Feraccru/Accrufer, for the treatment of iron deficiency (ID) in adults with any underlying cause. Royalties received from early sales of the product in the UK and Germany by partner Norgine are encouraging. The AEGIS-H2H study reported positive data, strengthening the product’s profile and leading to a €2.5m development milestone from Norgine. We expect a further ra